Justine Ryu, MD
Assistant ProfessorDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
About
Copy Link
Titles
Assistant Professor
Biography
Dr. Ryu is an Assistant Professor of Medicine (Hematology). She completed her fellowship at Beth Israel Deaconess Medical Center (BIDMC) where she also completed her residency and the T32 Blood Coagulation and Vascular Biology Program. She received her medical degree from Boston University School of Medicine.
Dr. Ryu cares for patients as part of the Smilow Classical Hematology Program in Orange, CT. She treats patients with thrombosis, anemia, bleeding and platelet disorders, and other hematological conditions and rare diseases. Her current area of research is focused on whole-genome sequencing in the All of Us Research Program and she has published numerous peer-reviewed manuscripts in journals including Blood Advances, Cell Reports, and Spine. During fellowship, she also completed the Program in Clinical Effectiveness through Harvard T.H. Chan School of Public Health to strengthen quantitative and analytic skills needed for clinical research.
Last Updated on September 27, 2023.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- All Institutions
- Classical Hematology at Smilow Cancer Hospital
- Hematology
- Internal Medicine
- Medical Oncology and Hematology
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Clinical Fellow
- Beth Israel Deaconess Medical Center (2023)
- T32 Postdoctoral Fellow in Hemostasis and Thrombosis
- Beth Israel Deaconess Medical Center (2020)
- Resident
- Boston Medical Center (2019)
- MD
- Boston University School of Medicine
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Justine Ryu's published research.
Publications Timeline
A big-picture view of Justine Ryu's research output by year.
Alfred Lee, MD, PhD
Jihoon Kim, PhD
Lucila Ohno-Machado, MD, MBA, PhD
33Publications
85Citations
Publications
2026
Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States
Lam B, Ryu J, Jafari O, Kim B, Ma S, Ranjan M, Jiang J, Li A. Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States. American Journal Of Hematology 2026 PMID: 41796432, DOI: 10.1002/ajh.70271.Peer-Reviewed Original ResearchConceptsCancer-associated venous thromboembolismCumulative incidence of venous thromboembolismIncidence of venous thromboembolismYear of cancer diagnosisElectronic health record systemsEpic electronic health record systemCancer diagnosisHealth record systemsCumulative incidenceRisk factorsVenous thromboembolismVenous thromboembolism typeUnited StatesMajor risk factorsDiagnosis dateUS CensusInsurance coverageOccurrence of venous thromboembolismEpidemiological studiesRecording systemCox regressionCollaborative datasetsPatient populationHomogeneous patient populationCancer typesPopulation-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder
Espada A, Haj A, Jurgens S, Eswaran H, Björkman L, Ryu J, Chaudhry S, Koyama S, Wang X, Choi S, Sanna-Cherchi S, Banerji A, Rämö J, Ellinor P, Grover S, Bendapudi P. Population-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder. Blood Advances 2026, 10: 931-938. PMID: 41026970, PMCID: PMC12905601, DOI: 10.1182/bloodadvances.2025017220.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHAE-C1INHVariant carriersC1INH deficiencyPopulation-scale datasetsThrombosis riskAssociated with hereditary angioedemaThrombotic disordersC1 inhibitorRisk of venous thromboembolismDeleterious variantsGenetic constraintsLifetime attributable riskGermline lossCoding variationThrombosis phenotypePeripheral arterial diseaseNon-cardioembolic ischemic strokeEffect size estimatesHereditary angioedemaNon-carriersAttributable riskC1INH levelsVenous thromboembolismArtery diseaseIndependent cohort
2025
Validation of a Risk Score for Cancer-Associated Thrombosis Using Nationwide EHR Data
Li A, Jafari O, Lam B, Jiang J, Kim B, Ma S, Zhou E, Tiong J, Chiang E, Ryu J, Amos C, La J, Fillmore N. Validation of a Risk Score for Cancer-Associated Thrombosis Using Nationwide EHR Data. JAMA Network Open 2025, 8: e2544428. PMID: 41288979, PMCID: PMC12648341, DOI: 10.1001/jamanetworkopen.2025.44428.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTrial exclusion criteriaRisk scoreHealth System sitesKhorana scorePrognostic studyVenous thromboembolismIncident venous thromboembolismExclusion criteriaCancer-associated thrombosisHigh riskEHR-dataRisk prediction modelVenous thromboembolism riskFollow-upHealth systemEHR dataEHR databaseContemporary cohortCancer associationVTE diagnosisAnticoagulant prescriptionActive cancerHematologic malignant neoplasmsCohort of patientsRisk groupsComparison of traditional vs novel approach to define cancer-associated bleeding
Tiong J, Chiang E, Jafari O, Ranjan M, Bandyo R, Ma S, Jiang J, Ryu J, Li A. Comparison of traditional vs novel approach to define cancer-associated bleeding. Blood 2025, 146: 1071. DOI: 10.1182/blood-2025-1071.Peer-Reviewed Original ResearchConceptsClinically relevant non-major bleedingClinically Relevant BleedingICD-10ICD-10 algorithmClinical notesMajor bleedingInternational ClassificationCancer patientsCohen's kappaSystematic reviewImplementation science effortsISTH definitionBleeding eventsInternational Classification of DiseasesTraditional chart reviewsClassification of diseasesInternational Society on ThrombosisSystemic therapy initiationNon-major bleedingSystematic review of PubMedPost-procedural bleedingBleeding codesReview of PubMedTrained physiciansAmbulatory settingFactor XI haploinsufficiency is protective against venous thromboembolism and myocardial infarction in population-scale multidimensional datasets
Espada A, Haj A, Jurgens S, Ryu J, Wang X, Choi S, Grover S, Ellinor P, Bendapudi P. Factor XI haploinsufficiency is protective against venous thromboembolism and myocardial infarction in population-scale multidimensional datasets. Blood 2025, 146: 1281. DOI: 10.1182/blood-2025-1281.Peer-Reviewed Original ResearchConceptsVariant carrier statusProtein functionCarrier statusLoss of functionProteomic dataVariant carriersBiallelic lossLoss of function variantsAshkenazi Jewish populationImpair protein functionVenous thromboembolismVenous thromboembolism riskWild-type individualsIn silico predictionPolygenic risk scoresDeleterious variantsUK Biobank (UKBPeripheral arterial diseaseNon-cardioembolic ischemic strokeFunctional variantsGermline variantsFounder variantAntithrombotic strategiesPlasma FXI levelsPopulation-scale biobanksEpidemiology of cancer-associated bleeding in a nationwide electronic health record database
Lim M, Gangaraju R, Jafari O, Tiong J, Chiang E, Ma S, Jiang J, Ryu J, Lam B, Ranjan M, Li A. Epidemiology of cancer-associated bleeding in a nationwide electronic health record database. Blood 2025, 146: 703. DOI: 10.1182/blood-2025-703.Peer-Reviewed Original ResearchConceptsAbstract Background PeopleElectronic health recordsTime-varying covariatesCancer diagnosisHealth systemBackground PeopleMonths prior to cancer diagnosisElectronic health record databaseActive cancer diagnosisHealth record databaseNewly diagnosed cancerLack of epidemiological dataHealth recordsAssociated with mortalityCohort representativePhenotyping algorithmsUS populationAnalytic cohortBilling diagnosisCensoring dateRecord databasePatient recordsFrequent cancerEpidemiological dataCox regressionEpidemiology of cancer-associated venous thromboembolism in a nationwide electronic healthrecord database
Lam B, Ryu J, Jafari O, Zhou E, Jiang J, Kim B, Ma S, Ranjan M, Lim M, Li A. Epidemiology of cancer-associated venous thromboembolism in a nationwide electronic healthrecord database. Blood 2025, 146: 4898. DOI: 10.1182/blood-2025-4898.Peer-Reviewed Original ResearchConceptsElectronic health recordsUpper extremity deep vein thrombosisTime-varying covariatesCancer diagnosisRisk of venous thromboembolismHealth systemHistory of venous thromboembolismHealthcare systemYear of cancer diagnosisMonths of cancer diagnosisEHR databaseLE-DVTCancer-associated thrombosisHigh riskAnnual VTE incidenceEpidemiological studiesAssociated with VTE riskVenous thromboembolismUpper GI cancerNewly diagnosed cancerBody mass indexSingle healthcare systemF2F visitsAcute venous thromboembolismVenous thromboembolism riskUse of population-scale multiomics to define the prothrombotic phenotype of Protein C deficiency
Espada A, Haj A, Jurgens S, Chaudhry S, Ryu J, Wang X, Choi S, Ellinor P, Grover S, Bauer K, Bendapudi P. Use of population-scale multiomics to define the prothrombotic phenotype of Protein C deficiency. Blood 2025, 146: 1278. DOI: 10.1182/blood-2025-1278.Peer-Reviewed Original ResearchConceptsVariant carrier statusCoding variantsCarrier statusVariant carriersLoss-of-function variantsProtein C antigen levelsType II variantRare germline variantsLow-penetrance phenotypeII variantsPolygenic risk scoresDeleterious variantsVenous thromboembolism riskUK Biobank (UKBProtein functionPC deficiencyPhenotypic dataGermline variantsProtein C functionThrombosis phenotypeVenous thromboembolismI variantsGermline geneticsGenetic testingNon-carriersCoagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
Haj A, Paul D, Jurgens S, Eswaran H, Weng L, Ryu J, Rodriguez Espada A, Chaudhry S, Feingold L, Burke K, Koyama S, Wang X, Francis J, Choi S, Mackman N, Bergmeier W, Burgin A, Rämö J, Ellinor P, Grover S, Bendapudi P. Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis. Nature Communications 2025, 16: 8176. PMID: 40890099, PMCID: PMC12402198, DOI: 10.1038/s41467-025-62789-5.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRisk of bleedingVenous thromboembolismHeterozygous lossHeterozygous carriersVariant carriersFactor XIISplice site variantFactor XII levelsCoagulation factor XIIFactor XII concentrationHeterozygous miceThrombin generationThromboembolismHaploinsufficient stateXII levelsWild-typeIntermediate phenotypesSite variantsBleedingPotential drug targetsHuman dataCoding regionGenetic variationF12 locusDrug targetsDevelopment and Validation of VTE-BERT Natural Language Processing Model for Venous Thromboembolism
Jafari O, Ma S, Lam B, Jiang J, Zhou E, Ranjan M, Ryu J, Bandyo R, Maghsoudi A, Peng B, Amos C, Oluyomi A, Fillmore N, La J, Li A. Development and Validation of VTE-BERT Natural Language Processing Model for Venous Thromboembolism. Journal Of Thrombosis And Haemostasis 2025 PMID: 40754035, PMCID: PMC12360494, DOI: 10.1016/j.jtha.2025.07.021.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHarris Health SystemIncident VTE eventsHealth systemNatural language processingVTE eventsVeterans Affairs Healthcare SystemNational Veterans Affairs Healthcare SystemManual chart reviewVenous thromboembolismDischarge summariesHealthcare systemHealthcare institutionsPatient levelNLP modelsAcute VTE eventAdvanced cancerClinical notesNatural language processing applicationsEpidemiological studiesNatural language processing modelsChart reviewLongitudinal studyBidirectional Encoder RepresentationsInternal validityLanguage processing models
Academic Achievements & Community Involvement
Copy Link
Clinical Care
Copy Link
Overview
Justine Ryu, MD, specializes in treating blood disorders, such as sickle cell anemia, platelet disorders, leukemia, lymphoma, multiple myeloma, atypical hemolytic uremic syndrome (aHUS), and polycythemia.
Dr. Ryu is an assistant professor at Yale School of Medicine.
Clinical Specialties
Hematology
Fact Sheets
Bleeding Disorders
Learn More on Yale MedicineSickle Cell Disease
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
- December 18, 2024
Yale research advances presented at American Society of Hematology annual meeting
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- November 28, 2023
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Get In Touch
Copy Link
Contacts
Email
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.